NCT05968768: To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)
- State
- Under way
- Phase
- Phase 2
- People
- 24 planned
- Started
- 24 Oct 2023
- Primary completion
- 1 May 2027
- Arms
- Experimental - Naxitamab Arm
- Results
- None posted
- 1 Aug 2023: Trial registered
- 24 Oct 2023: Trial started